JP2025513454A5 - - Google Patents

Info

Publication number
JP2025513454A5
JP2025513454A5 JP2024562078A JP2024562078A JP2025513454A5 JP 2025513454 A5 JP2025513454 A5 JP 2025513454A5 JP 2024562078 A JP2024562078 A JP 2024562078A JP 2024562078 A JP2024562078 A JP 2024562078A JP 2025513454 A5 JP2025513454 A5 JP 2025513454A5
Authority
JP
Japan
Prior art keywords
pain
compound
alkyl
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024562078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513454A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/019478 external-priority patent/WO2023205468A1/en
Publication of JP2025513454A publication Critical patent/JP2025513454A/ja
Publication of JP2025513454A5 publication Critical patent/JP2025513454A5/ja
Pending legal-status Critical Current

Links

JP2024562078A 2022-04-22 2023-04-21 疼痛の治療のためのヘテロアリール化合物 Pending JP2025513454A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263333881P 2022-04-22 2022-04-22
US63/333,881 2022-04-22
PCT/US2023/019478 WO2023205468A1 (en) 2022-04-22 2023-04-21 Heteroaryl compounds for the treatment of pain

Publications (2)

Publication Number Publication Date
JP2025513454A JP2025513454A (ja) 2025-04-24
JP2025513454A5 true JP2025513454A5 (enExample) 2026-04-28

Family

ID=86382967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024562078A Pending JP2025513454A (ja) 2022-04-22 2023-04-21 疼痛の治療のためのヘテロアリール化合物

Country Status (7)

Country Link
US (1) US20250388543A1 (enExample)
EP (1) EP4511115A1 (enExample)
JP (1) JP2025513454A (enExample)
CN (1) CN119546580A (enExample)
AU (1) AU2023257313A1 (enExample)
CA (1) CA3256248A1 (enExample)
WO (1) WO2023205468A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025256572A1 (zh) * 2024-06-13 2025-12-18 海思科医药集团股份有限公司 一种Nav1.8抑制剂及其在医药上的应用
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US7493493B2 (en) 2003-12-12 2009-02-17 International Business Machines Corporation Method and apparatus for password generation
AU2005266090A1 (en) 2004-07-23 2006-02-02 Pfizer Inc. Pyridine derivatives
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
CA2684105C (en) 2007-05-03 2011-09-06 Pfizer Limited Pyridine derivatives
MX2011006904A (es) 2008-12-26 2011-07-20 Dainippon Sumitomo Pharma Co Compuesto heterociclico biciclico novedoso.
CA2760946C (en) 2009-05-07 2019-06-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011026240A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
KR101923367B1 (ko) 2011-02-02 2018-12-04 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드
MX2013009393A (es) 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
CN103517910B (zh) 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
PH12013501865A1 (en) 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
CA2850925C (en) 2011-10-26 2017-01-10 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
US9012443B2 (en) 2011-12-07 2015-04-21 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
NZ627259A (en) 2012-01-16 2016-12-23 Vertex Pharma Pyran-spirocyclic piperidine amides as modulators of ion channels
JP6002785B2 (ja) 2012-02-03 2016-10-05 ファイザー・インク ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
CA2898653C (en) 2013-01-31 2021-09-28 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
RU2683788C2 (ru) 2013-01-31 2019-04-02 Вертекс Фармасьютикалз Инкорпорейтед Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов
RS56015B1 (sr) 2013-01-31 2017-09-29 Vertex Pharma Piridon amidi kao modulatori natrijumovih kanala
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
UA119147C2 (uk) 2013-07-19 2019-05-10 Вертекс Фармасьютікалз Інкорпорейтед Сульфонаміди як модулятори натрієвих каналів
CA2931550C (en) 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
WO2015157559A2 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins for the treatment of pain
EA032928B1 (ru) 2015-03-02 2019-08-30 Эмджен Инк. Бициклические кетосульфонамидные соединения
ES2895155T3 (es) 2015-09-30 2022-02-17 Siteone Therapeutics Inc Saxitoxinas modificadas en 11,13 para el tratamiento del dolor
CN110831945B (zh) 2017-03-29 2023-08-08 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
US11279706B2 (en) 2017-03-29 2022-03-22 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
EP3625214B1 (en) 2017-05-16 2022-07-06 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
AU2019302534B2 (en) 2018-07-09 2024-10-03 Lieber Institute, Inc. Pyridazine compounds for inhibiting NaV1.8
CA3105657A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
JP7288051B2 (ja) 2018-11-02 2023-06-06 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害薬としての2-アミノ-N-ヘテロアリール-ニコチンアミド類
US12344595B2 (en) 2018-11-02 2025-07-01 Merck Sharp & Dohme Llc 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors
EP3891157A4 (en) 2018-12-05 2022-08-31 Merck Sharp & Dohme Corp. 4-AMINO- OR 4-ALKOXY-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATE SODIUM CHANNELS
US20220073471A1 (en) 2019-01-04 2022-03-10 Jiangsu Hengrui Medicine Co., Ltd. 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
BR112021013557A2 (pt) 2019-01-11 2021-09-21 Grünenthal GmbH Amidas de pirrolidina substituídas iii
TW202043200A (zh) 2019-01-25 2020-12-01 大陸商江蘇恆瑞醫藥股份有限公司 2-側氧基-1,2-二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
MX2021015605A (es) 2019-06-27 2022-02-16 Glaxosmithkline Ip Dev Ltd Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8.
CN112300051A (zh) 2019-07-31 2021-02-02 明慧医药(上海)有限公司 一种选择性钠通道调节剂及其制备和应用
CN112300069A (zh) 2019-07-31 2021-02-02 明慧医药(上海)有限公司 一种选择性钠通道调节剂及其制备和应用
CN112390745B (zh) 2019-08-19 2022-10-21 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
WO2021032074A1 (zh) 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
CN112441969A (zh) 2019-08-30 2021-03-05 明慧医药(上海)有限公司 一种选择性钠通道调节剂及其制备和应用
BR112022004495A8 (pt) 2019-09-12 2023-04-18 Jiangxi Jemincare Group Co Ltd Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmos
CN111217776A (zh) 2020-01-19 2020-06-02 中国人民解放军军事科学院军事医学研究院 含苯并杂环结构的酰胺衍生物、组合物和应用
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
CA3183948A1 (en) 2020-06-10 2021-12-16 Amgen Inc. Heteroalkyl dihydroquinoline sulfonamide compounds
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
US12516046B2 (en) 2020-06-17 2026-01-06 Merck Sharp & Dohme Llc 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors
US11802122B2 (en) 2020-06-17 2023-10-31 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors
CN115697327A (zh) 2020-06-17 2023-02-03 默沙东有限责任公司 作为nav1.8抑制剂的5-氧代-吡咯烷-3-甲酰胺
EP4196482B1 (en) 2020-08-14 2025-10-01 SiteOne Therapeutics, Inc. Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
CN111808019B (zh) 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
CN114591293A (zh) 2020-12-07 2022-06-07 成都康弘药业集团股份有限公司 作为Nav1.8抑制剂的并环化合物及其用途
CN112225695B (zh) 2020-12-15 2021-03-02 上海济煜医药科技有限公司 一种氮氧化合物及其制备方法和用途
CN112457294B (zh) 2021-01-27 2021-06-04 上海济煜医药科技有限公司 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途
GEP20257795B (en) 2021-05-07 2025-09-25 Merck Sharp & Dohme Llc Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
AU2022270061B2 (en) 2021-05-07 2026-02-19 Merck Sharp & Dohme Llc Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
TW202317520A (zh) 2021-06-15 2023-05-01 德商歌林達有限公司 經取代之吡唑醯胺

Similar Documents

Publication Publication Date Title
JP2025513454A5 (enExample)
JP7770691B2 (ja) 抗ウイルス活性等の生理活性を有する化合物
JP2021534124A5 (enExample)
KR102585108B1 (ko) 세균 감염의 치료를 위한 항미생물성 폴리믹신
JP2017518959A5 (enExample)
RU2009102252A (ru) Хиноксалинилмакроциклические ингибиторы серинпротеазы вируса гепатита с
JP2022524974A5 (enExample)
RU2010101611A (ru) Полициклические производные гуанина и способы их применения
RU2010126056A (ru) Органические соединения
RU2639153C2 (ru) Трициклическое бензоксабороловое соединение, способ его получения и его применение
JP2022522694A5 (enExample)
WO2011026107A1 (en) Phthalanilate compounds and methods of use
EP2139889B1 (en) Amino-naphthyridine derivatives
EP4457214A2 (en) Dimethyltryptamine analogues as nitric oxide delivery drugs
JP2010505865A5 (enExample)
JP2013528659A5 (enExample)
RU2003134629A (ru) Соединения цефема
EP1972338A1 (en) Anti-infective agents
JP2022509763A5 (enExample)
JP7834842B2 (ja) 非対称gpr84拮抗剤およびその使用
JP2021530465A5 (enExample)
CN1436173A (zh) 羟基甲脒衍生物及含有该衍生物的药物
WO2023224128A1 (ja) 線維症の治療又は予防のための医薬組成物
KR20180020119A (ko) 새로운 5형포스포디에스테라아제 억제제 및 그 용도
TWI892182B (zh) 吡唑化合物、製備方法、其醫藥組合物及其用途